{"brief_title": "Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants", "brief_summary": "OBJECTIVES: I. Assess the efficacy and safety of antenatal administration of thyrotropin-releasing hormone to women in premature labor to improve pulmonary outcomes in preterm infants.", "detailed_description": "PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study. Patients are randomized to receive antenatal thyrotropin-releasing hormone or placebo. Patients receive thyrotropin-releasing hormone or placebo intravenously over 20 minutes every 8 hours for 4 doses. Infants are assessed for survival and chronic lung disease until day 28 after birth, and again at 36 postmenstrual weeks.", "condition": ["Respiratory Distress Syndrome"], "intervention_type": ["Drug"], "intervention_name": ["thyrotropin-releasing hormone"], "criteria": "- Pregnant women in active labor with 24-29 weeks gestation - Not eligible if any of the following is present: Bleeding Infection Hypertension (greater than 140/90 mmHg) Fetus with hydrops or life-threatening anomalies One dead fetus in multiple pregnancy", "gender": "Female", "minimum_age": "20 Years", "maximum_age": "36 Years", "healthy_volunteers": "No", "keyword": "respiratory distress syndrome", "mesh_term": ["Respiratory Distress Syndrome, Newborn", "Respiratory Distress Syndrome, Adult", "Hormones", "Thyrotropin-Releasing Hormone", "Calcitonin"], "id": "NCT00004840"}